Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors

Table 8

Multivariate Cox proportional hazards regression models for overall survival.

Variable	Multivariate analysis
	HR	95% CI	value
Child-Pugh class
B vs. A	0.693	0.168-2.861	0.612
CNLC stage
IIIb vs. IIb and IIIa	3.727	0.778-17.860	0.100
AFP
≥400 vs. <400 ng/ml	1.830	0.617-5.431	0.276
PVTT
Yes vs. none	8.943	1.129-70.813	0.038
NLR
≥5 vs. <5	3.398	1.050-10.995	0.041

Abbreviations: ECOG: Eastern Cooperative Oncology Group; HBV: hepatitis B virus; BMI: body mass index; BCLC: Barcelona Clinic Liver Cancer; CNLC: China Liver Cancer staging; RFA: radiofrequency ablation; TACE: transarterial chemoembolization; RT: radiotherapy; PVTT: portal vein tumor thrombus; AFP: α-fetoprotein; SII: systemic immune-inflammation index; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio.